SFRP1-Silencing GapmeR-Loaded Lipid-Polymer Hybrid Nanoparticles for Bone Regeneration in Osteoporosis: Effect of Dosing and Targeting Strategy
Erik Briffault,Ricardo Reyes,Patricia Garcia-Garcia,Helena Rouco,Luis Diaz-Gomez,Maria Arnau,Carmen Evora,Patricia Diaz-Rodriguez,Araceli Delgado
DOI: https://doi.org/10.2147/ijn.s476546
IF: 7.033
2024-11-27
International Journal of Nanomedicine
Abstract:Erik Briffault, 1, 2 Ricardo Reyes, 2, 3 Patricia Garcia-Garcia, 1, 2 Helena Rouco, 1 Luis Diaz-Gomez, 4 Maria Rosa Arnau, 2, 5 Carmen Evora, 1, 3 Patricia Diaz-Rodriguez, 2, 4 Araceli Delgado 1, 2 1 Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38206, Spain; 2 Institute of Biomedical Technologies (ITB), Universidad de La Laguna, La Laguna, 38320, Spain; 3 Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, 38200, Spain; 4 Department of Pharmacology, Pharmacy and Pharmaceutical Technology, I+D Farma Group (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain; 5 Servicio de Estabulario, Universidad de La Laguna, La Laguna, 38206, Spain Correspondence: Patricia Diaz-Rodriguez; Araceli Delgado, Email ; Introduction: Osteoporosis is a metabolic disorder characterized by the loss of bone mass and density. Nucleic acid-based therapies are among the most innovative approaches for osteoporosis management, although their effective delivery to bone tissue remains a challenge. In this work, SFRP1-silencing GampeR loaded-nanoparticles were prepared and functionalized with specific moieties to improve bone targeting and, consequently, therapeutic efficacy. SFRP1-silencing would promote osteoblastic differentiation by enhancing the WNT/β-catenin pathway and thus diminishing the progression of osteoporosis. Methods: A nucleic acid-based delivery system consisting of lipid-polymer hybrid nanoparticles (LPNPs) loading a GapmeR for SFRP1 silencing was developed and further functionalized with two bone-targeting moieties: a specific aptamer (Apt) for murine mesenchymal stem cells and an antiresorptive drug, namely alendronate (ALD). These systems were tested in vivo in osteoporotic mice at different dosage regimens to analyze dose dependence in bone-forming activity and potential toxicity. The quality of trabecular and cortical bone was assessed by both micro computed tomography (micro-CT) and histological and histomorphometric analyses. Early and late osteogenesis were quantified by immunohistochemistry. Results: Results showed that functionalizing LPNPs loaded with an SFRP1-silencing GapmeR using both Apt and ALD improved bone quality and enhanced osteogenesis following a dose–effect relationship, as revealed by micro-CT, histological and immunohistochemical analyses. In contrast, non-functionalized LPNPs did not produce these effects. Conclusion: These findings highlight the relevance of proper targeting and dosage in nucleic acid-based therapeutics, proving to be crucial for exerting their therapeutic effect: a deficient targeting strategy and/or dosage may result in the therapeutic failure of an adequate gene therapy agent. Keywords: osteoporosis, bone targeting, nanoparticle dose-effect, gene therapy, aptamer, alendronate, micro-CT Graphical Despite the vast efforts and resources focused on the stimulation of bone formation in systemic bone-related pathologies such as osteoporosis, the improvement of the osseous tissue quality remains challenging. 1 The associated diminished bone strength and stiffness increases the risk of bone fractures after low-energy injuries leading to fragility fractures. These fractures represent an economic burden and are only going to become an ever-increasing problem with the aging of the population. Just in 2010 fragility fracture treatment represented 22.42 billion euros in Europe. 2 Moreover, the established pro-degradative environment that imbalances the normal tissue homeostasis impairs bone formation, thus increasing the risk of non-union bone fractures and implant failure. 3–8 Different strategies have been screened in order to counterbalance this situation, including antiresorptive drugs such as bisphosphonates and RANKL inhibitors or anabolic molecules such as teriparatide, abaloparatide and romosozumab. 9 However, significant drawbacks such as osteonecrosis of the jaw and atypical femoral fractures, frequently described in patients with high-dose or long-term treatments, have limited the use of these therapeutic molecules. 10 Improvements in the nucleic acid-based therapeutic stability and the high throughput discovery of genetic targets have exponentially increased the potential of oligonucleotide therapies to correct or modify cell function. 11 Gene th -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology